TY - JOUR
T1 - Synthesis of macrocyclic nucleoside antibacterials and their interactions with MraY
AU - Nakaya, Takeshi
AU - Yabe, Miyuki
AU - Mashalidis, Ellene H.
AU - Sato, Toyotaka
AU - Yamamoto, Kazuki
AU - Hikiji, Yuta
AU - Katsuyama, Akira
AU - Shinohara, Motoko
AU - Minato, Yusuke
AU - Takahashi, Satoshi
AU - Horiuchi, Motohiro
AU - Yokota, Shin ichi
AU - Lee, Seok Yong
AU - Ichikawa, Satoshi
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - The development of new antibacterial drugs with different mechanisms of action is urgently needed to address antimicrobial resistance. MraY is an essential membrane enzyme required for bacterial cell wall synthesis. Sphaerimicins are naturally occurring macrocyclic nucleoside inhibitors of MraY and are considered a promising target in antibacterial discovery. However, developing sphaerimicins as antibacterials has been challenging due to their complex macrocyclic structures. In this study, we construct their characteristic macrocyclic skeleton via two key reactions. Having then determined the structure of a sphaerimicin analogue bound to MraY, we use a structure-guided approach to design simplified sphaerimicin analogues. These analogues retain potency against MraY and exhibit potent antibacterial activity against Gram-positive bacteria, including clinically isolated drug resistant strains of S. aureus and E. faecium. Our study combines synthetic chemistry, structural biology, and microbiology to provide a platform for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.
AB - The development of new antibacterial drugs with different mechanisms of action is urgently needed to address antimicrobial resistance. MraY is an essential membrane enzyme required for bacterial cell wall synthesis. Sphaerimicins are naturally occurring macrocyclic nucleoside inhibitors of MraY and are considered a promising target in antibacterial discovery. However, developing sphaerimicins as antibacterials has been challenging due to their complex macrocyclic structures. In this study, we construct their characteristic macrocyclic skeleton via two key reactions. Having then determined the structure of a sphaerimicin analogue bound to MraY, we use a structure-guided approach to design simplified sphaerimicin analogues. These analogues retain potency against MraY and exhibit potent antibacterial activity against Gram-positive bacteria, including clinically isolated drug resistant strains of S. aureus and E. faecium. Our study combines synthetic chemistry, structural biology, and microbiology to provide a platform for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.
UR - http://www.scopus.com/inward/record.url?scp=85144247611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144247611&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-35227-z
DO - 10.1038/s41467-022-35227-z
M3 - Article
C2 - 36539416
AN - SCOPUS:85144247611
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 7575
ER -